ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $400,867 | -74.7% | 75,493 | -54.5% | 0.00% | – |
| Q2 2023 | $1,582,752 | +7.6% | 166,081 | +24.2% | 0.00% | – |
| Q1 2023 | $1,471,294 | -49.1% | 133,754 | -31.5% | 0.00% | -100.0% |
| Q4 2022 | $2,890,470 | +25.7% | 195,302 | +62.2% | 0.00% | – |
| Q3 2022 | $2,300,000 | +75.0% | 120,395 | +95.2% | 0.00% | – |
| Q2 2022 | $1,314,000 | +77.6% | 61,681 | +60.5% | 0.00% | – |
| Q1 2022 | $740,000 | -65.1% | 38,432 | -62.4% | 0.00% | – |
| Q4 2021 | $2,122,000 | +106.4% | 102,334 | +137.8% | 0.00% | – |
| Q3 2021 | $1,028,000 | -69.4% | 43,035 | -65.0% | 0.00% | – |
| Q2 2021 | $3,356,000 | +151.6% | 122,990 | +166.8% | 0.00% | – |
| Q1 2021 | $1,334,000 | +112.4% | 46,102 | +106.3% | 0.00% | – |
| Q4 2020 | $628,000 | -36.6% | 22,348 | -33.9% | 0.00% | – |
| Q3 2020 | $990,000 | +182.1% | 33,797 | +191.6% | 0.00% | – |
| Q2 2020 | $351,000 | – | 11,592 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |